Ohio is currently home to 3201 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069
Recruiting
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
03/28/2025
Locations: Summa Health System - Akron Campus, Akron, Ohio
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma, Ann Arbor Stage III Lymphoma, Ann Arbor Stage IV Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Gastroesophageal Junction Adenocarcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Invasive Breast Carcinoma, Kidney Carcinoma, Malignant Hepatobiliary Neoplasm, Malignant Solid Neoplasm, Melanoma, Muscle-Invasive Bladder Carcinoma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma, RISS Stage III Plasma Cell Myeloma, Sarcoma, Stage I Bladder Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage I Colorectal Cancer AJCC v6 and v7, Stage I Esophageal Cancer AJCC V7, Stage I Gastric Cancer AJCC V7, Stage I Lung Cancer AJCC v7, Stage I Ovarian Cancer AJCC v6 and v7, Stage I Pancreatic Cancer AJCC v6 and v7, Stage I Prostate Cancer AJCC v7, Stage I Uterine Corpus Cancer AJCC v7, Stage II Bladder Cancer AJCC v6 and v7, Stage II Breast Cancer AJCC v6 and v7, Stage II Colorectal Cancer AJCC v7, Stage II Esophageal Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage II Lung Cancer AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage II Prostate Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage III Bladder Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Bladder Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Lung Cancer AJCC v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Thyroid Gland Carcinoma
Register for Updates
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
NCT04988555
Recruiting
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in adult patients with acute leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
Register for Updates
North American Comfilcon A Clinical Study
NCT06902584
Recruiting
The main objective of this study is to demonstrate acceptable safety and effectiveness (performance) of comfilcon A Sphere, Toric, Multifocal, Toric Multifocal and Energys lenses, when used in the general population.
Gender:
ALL
Ages:
Between 8 years and 75 years
Trial Updated:
03/27/2025
Locations: ProCare Vision Center, Granville, Ohio
Conditions: Astigmatism, Presbyopia, Ametropia
Register for Updates
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
NCT06070350
Recruiting
The MATIC-2 is a multicenter clinical trial enrolling children who are less than 18 years of age with hemorrhagic shock potentially needing significant blood transfusion. The primary objective of the clinical trial is to determine the effectiveness of Low Titer Group O Whole Blood (LTOWB) compared to component therapy (CT), and Tranexamic Acid (TXA) compared to placebo in decreasing 24-hour all-cause mortality in children with traumatic life threatening hemorrhage.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
03/27/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Hemorrhagic Shock, Trauma Injury
Register for Updates
Nurse Family Partnership for Women With Previous Live Births
NCT05887115
Recruiting
The goal of this clinical trial is to test the Nurse Family Partnership (NFP) in mothers with previous live births (multiparous or multip individuals). The main aims are: Specific Aim 1-Determine the effectiveness of NFP among multiparous women for reducing maternal morbidity and improving pregnancy outcomes. Specific Aim 2-Determine the effectiveness of NFP among index children (child from pregnancy when mother was enrolled) of multiparous women for improving child outcomes. Specific Aim 3 (... Read More
Gender:
FEMALE
Ages:
Between 16 years and 46 years
Trial Updated:
03/27/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Pregnancy, High Risk, Child Development, Post Partum Depression
Register for Updates
Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers
NCT05758545
Recruiting
The purpose of this clinical trial is to evaluate the safety and effectiveness of the treatment with the COMS One device in subjects with refractory diabetic foot ulcers (DFUs). The prospective randomized, double-blinded, sham-controlled trial is designed to demonstrate superiority of wound closure of the COMS One device to a sham-control device through 24 weeks post-application, when each is administered in conjunction with standard of care (SOC) in the treatment of DFUs.
Gender:
ALL
Ages:
Between 22 years and 90 years
Trial Updated:
03/27/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Diabetic Foot Ulcer
Register for Updates
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
NCT05642611
Recruiting
This phase III trial compares the effect of 3 study approaches in preventing chemotherapy-induced peripheral neuropathy: 1) cryocompression, 2) continuous compression, and 3) low cyclic compression. Taxane chemotherapy drugs, such as paclitaxel or docetaxel, can cause a nerve disorder called peripheral neuropathy, which can cause numbness, tingling, or pain in the arms and legs. The 3 study approaches will use a device, called the Paxman Limb Cryocompression System, made of wraps that cool and/o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio
Conditions: Malignant Solid Neoplasm
Register for Updates
Intervention to Improve Driving Practices Among High-Risk Teen Drivers
NCT04317664
Recruiting
The purpose of this study is to test the effects of an in-vehicle driving feedback technology, with and without parent communication training, on risky driving events, unsafe driving behaviors, and subsequent traffic violations among teens who have recently received a moving traffic violation.
Gender:
ALL
Ages:
Between 16 years and 17 years
Trial Updated:
03/27/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Drive, Recidivism, Communication, Feedback, Psychological
Register for Updates
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors
NCT03647163
Recruiting
The safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion of the trial will be used for the expansion portion. The study has been conducted with a dose of 1.7 ×... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
Conditions: Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
Register for Updates
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
NCT03622359
Recruiting
The aim of this clinical study is to 1) establish a healthy database for nuclear perfusion imaging of the lower extremities and 2) assess the prognostic value of radiotracer-based perfusion imaging for predicting clinical outcomes in patients with peripheral artery disease (PAD) who are undergoing lower extremity revascularization procedures. We hypothesize that radiotracer imaging of the lower extremities will provide a sensitive non-invasive imaging tool for quantifying regional abnormalities... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Diabetes Mellitus, Peripheral Artery Disease, Chronic Limb-Threatening Ischemia
Register for Updates
International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
NCT02305654
Recruiting
This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provi... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Squamous Cell Carcinoma of the Penis, Usual Type
Register for Updates
Neural Correlates During Alcohol Intoxication
NCT06118580
Recruiting
Alcohol intoxication is responsible for a large proportion of violent crime/assault and personal injury in our society. While a number of variables have been associated with alcohol-related aggression, high trait aggression and impaired executive function have been identified as key factors. Both Alcohol Use Disorder (AUD) and Impulsive Aggression behavior (AGG) are related to impaired social-emotional information processing (SEIP) whereby social threat cues, especially ones that are ambiguous i... Read More
Gender:
ALL
Ages:
Between 21 years and 55 years
Trial Updated:
03/26/2025
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Alcohol Use Disorder, Intermittent Explosive Disorder
Register for Updates